Loading…
Prevalence and Prediction of Ruxolitinib Treatment Emergent Thrombocytopenia in Myelofibrosis
Introduction Ruxolitinib (rux) treatment for myelofibrosis (MF) is frequently complicated by the development of thrombocytopenia, leading to dose reduction and treatment discontinuation, an event which is associated with poor outcomes. With the recent availability of JAK inhibitors that are safe and...
Saved in:
Published in: | Blood 2023-11, Vol.142 (Supplement 1), p.1830-1830 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Introduction
Ruxolitinib (rux) treatment for myelofibrosis (MF) is frequently complicated by the development of thrombocytopenia, leading to dose reduction and treatment discontinuation, an event which is associated with poor outcomes. With the recent availability of JAK inhibitors that are safe and effective in thrombocytopenic MF patients, identifying predictors for rux-induced thrombocytopenia may allow for personalized JAK inhibitor selection in the upfront setting.
Methods
We conducted a retrospective cohort study of JAK inhibitor naïve MF patients treated with rux at two large academic institutions (Mount Sinai and Moffitt Cancer Center). Included patients had a baseline platelet count of ≥100 x 10 9/L. The primary outcome was the development of a platelet count of |
---|---|
ISSN: | 0006-4971 1528-0020 |
DOI: | 10.1182/blood-2023-179937 |